Anesthesia and Non-small Cell Lung Cancer Recurrence
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Samsung Medical Center
- Principal Investigator
- Hyun Joo Ahn, MDDepartment of Anesthesiology and Pain Medicine, Samsung Medical Center
- Intervention
- Propofol(drug)
- Enrollment
- 5384 target
- Eligibility
- 19 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- Samsung Medical Center, Seoul, Seoul-teukbyeolsi, South Korea
Collaborators
Seoul National University Hospital · Asan Medical Center · Severance Hospital · Seoul St. Mary's Hospital · Korea University Guro Hospital · DongGuk University · Inha University Hospital · Konkuk University Medical Center · Ewha Womans University · Chungnam National University Hospital · University of Virginia · Memorial Sloan Kettering Cancer Center · Yale University · Mayo Clinic · University of Texas Southwestern Medical Center · University Hospitals Coventry and Warwickshire NHS Trust · Khon Kaen University · King Chulalongkorn Memorial Hospital · The Affiliated Hospital of Qingdao University · Beijing Hospital · All India Institute of Medical Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06330038 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →